by The plasmid DNA manufacturing market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 22.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Plasmid DNA is a form of DNA that can replicate independently of chromosomal DNA within a cell or in an organism. Plasmid DNA is widely used in various gene and cell therapy applications such as gene therapy, genetic vaccines, immunotherapies, and cancer therapies. Plasmid DNA manufacturing involves the cultivation of bacteria to produce plasmid DNA extracts on an industrial scale for therapeutic applications. Plasmids are engineered to carry therapeutic genes used in gene therapy applications. They are also used to develop genetic vaccines where they are engineered to express viral antigens to induce immune response.
Market Dynamics:
The rapid growth in the gene and cell therapy industry is fueling the demand for plasmid DNA, thereby driving the plasmid DNA manufacturing market growth. Gene therapies involve the introduction of functional genes into patient’s cells and tissues to treat diseases. As per some estimates, currently over 2,000 gene therapy clinical trials are underway globally. Additionally, the increasing R&D investments by pharmaceutical companies in developing gene and cell therapies is also propelling the market growth. Moreover, continuous technological advancements in plasmid DNA manufacturing technologies such as the incorporation of continuous manufacturing technologies are helping in increasing yields and reducing manufacturing costs. However, stringent regulations associated with gene therapies may negatively impact the market growth.
Segment Analysis
The Plasmid DNA Manufacturing Market can be segmented based on type into research-grade plasmid DNA and GMP-grade plasmid DNA. GMP-grade plasmid DNA is dominating the market as it is essential for gene therapy and DNA vaccination applications which require high purity and safety standards.
PEST Analysis
Political: Stringent regulations regarding the manufacturing and transportation of GMP-grade DNA plasmids in various regions are positively impacting the market.
Economic: Rising investments in R&D activities related to cell and gene therapies are fueling the demand for high-quality plasmid DNA, driving the market growth.
Social: Increasing prevalence of cancer and other chronic diseases have boosted research focusing on advanced treatment approaches such as gene therapy and DNA vaccination, favoring market expansion.
Technological: Recent advancements in DNA manufacturing technologies such as continuous-flow methods are helping improve yields and ensure regulatory compliance, supporting the market.
Key Takeaways
The global Plasmid DNA Manufacturing Market is expected to witness high growth, exhibiting 22% CAGR over the forecast period of 2023 to 2030, due to increasing R&D spending on gene therapy development. The market size for Plasmid DNA Manufacturing was valued at US$ 901.2 Bn in 2023.
Regional analysis:
North America dominated the market in 2023 due to huge Government and private investments in cell and gene therapy research in the US. Asia Pacific is anticipated to be the fastest growing market owing to surging penetration of gene therapy and DNA vaccines in China, India, and South Korea.
Key players analysis:
Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
